Dyadic Intl Rg
Dyadic International, Inc. uses its patented C1 biotech platform to produce cost‑effective industrial enzymes and recombinant proteins for life sciences, food, and bioindustrial markets, and is developing a Phase‑1 SARS‑CoV‑2 RBD vaccine candidate.
Headquarters: United States (USA)
- Website: Visit Site 🔗
- Type: Corporation
Company Profile
- Sector: Professional Services
- Industry: Biotechnology Research
- Employees: 6
- HQ: Jupiter
Unlock the full potential.
Upgrade
Get access to Relative P/E Ratio Valuation Histogram.